Physician profile
Scott B Hearth
NPI 1548366727
$4,761.81
in general payments reported to CMS, 2019-2025
29 companies · $781 in 2025
The $781 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $533 · 2021: $527 · 2022: $872 · 2023: $863 · 2024: $567 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,135.70 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $772.25 | 2019-2025 | |
| Janssen Biotech, INC. | $467.76 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $441.40 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $406.15 | 2019-2025 | Jublia |
| Merz North America, INC. | $229.40 | 2019-2022 | |
| Dermira, INC. | $203.24 | 2019-2021 | |
| Genzyme Corporation | $195.17 | 2022-2025 | |
| Galderma Laboratories, L.P. | $178.26 | 2019-2025 | Epsolay, Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $159.64 | 2019-2024 | |
| Amgen INC. | $158.74 | 2022-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $155.38 | 2020-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $139.40 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $138.24 | 2022-2025 | Dupixent |
| Dermavant Sciences, INC. | $126.50 | 2022-2024 | Vtama |
| Leo Pharma INC. | $125.97 | 2019-2025 | Anzupgo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $122.31 | 2020 | |
| Biofrontera INC. | $115.34 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $112.66 | 2019-2021 | |
| Allergan, INC. | $105.00 | 2020-2022 | |
| Pfizer INC. | $93.93 | 2019-2021 | |
| Prugen, INC. Pharmaceuticals | $82.48 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $79.49 | 2023-2025 | Zoryve |
| Epi Health, LLC | $52.29 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $19.24 | 2024 | Ycanth |
| Organon LLC | $18.88 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $16.70 | 2019 | |
| Celgene Corporation | $16.53 | 2019 | |
| Strata Skin Sciences, INC. | $16.01 | 2025 | Xtrac |
| Mayne Pharma Commercial LLC | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hearth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.